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Abstract: Chitosan is a widely available, mucoadhesive polymer that is able to increase cellular 
permeability and improve the bioavailability of orally administered protein drugs. It can also be 
readily formed into nanoparticles able to entrap drugs or condense plasmid DNA. Studies on the 
formulation and oral delivery of such chitosan nanoparticles have demonstrated their efficacy in 
enhancing drug uptake and promoting gene expression. This review summarizes some of these 
findings and highlights the potential of chitosan as a component of oral delivery systems.  
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Introduction
Effective oral drug administration is desirable but challenging owing to the nature of the 
gastrointestinal tract. The highly acidic pH in the stomach and the presence of enzymes 
such as pepsin can cause protein degradation (Allemann et al 1998). Secreted pancreatic 
enzymes in the lumen of the intestine and membrane-bound brush-border enzymes may 
also cause substantial loss of drug activity (Bernkop-Schnürch and Krajicek 1998). 
Finally, the physical barrier of the intestinal cells must be crossed before a drug can 
reach the circulation. This is especially problematic for macromolecular drugs too 
large to pass between cells through the paracellular pathway and too hydrophilic to 
be absorbed passively through cell membranes (Goldberg and Gomez-Orellana 2003). 
These obstacles lead to poor oral bioavailability for many protein and peptide drugs. 
Increasingly, nucleic acids are also being applied as drugs, either as components of 
a vaccine or in gene therapy approaches. Many of the issues facing oral gene delivery 
are similar to those of oral protein delivery, including protection in the stomach and 
intestines and transport into or across intestinal epithelial cells. Additional barriers to 
effective DNA delivery include endosomal escape, nuclear localization, transcription, 
translation, protein processing, and protein secretion (if necessary) into plasma. 
One proposed method to overcome these physical and degradative barriers is 
formulation of the drug or gene into nanoparticles. Such particles may partially protect 
the entrapped drug or gene from degradation and improve cellular uptake through 
endocytosis. While a variety of polymers and lipids have been employed to form 
drug- or gene-loaded nanoparticles, one biodegradable polymer that has received a 
good deal of recent attention as a component of oral drug and gene delivery systems 
is chitosan.
Properties of chitosan
Chitosan is a polysaccharide derived from the partial deacetylation of chitin, primarily 
from crustacean and insect shells. It consists of repeating units of glucosamine and N-
acetyl-glucosamine, the proportions of which determine the degree of deacetylation of 
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the polymer. With a pKa of approximately 6.5 on the amine 
groups, chitosan is insoluble at neutral pH but is soluble 
and positively charged at acidic pH (Singla and Chawla 
2001; Hejazi and Amiji 2003). By affecting the number 
of protonatable amine groups, the degree of deacetylation 
fundamentally determines the polymer properties including 
solubility, hydrophobicity, and the ability to interact 
electrostatically with polyanions (Kiang, Wen, et al 2004; 
Huang et al 2005). The solubility of chitosan in neutral 
and basic pH can be improved by quaternization to form 
trimethyl chitosan derivatives (van der Merwe et al 2004). 
The molecular weight of chitosan, which is available over a 
wide range, is also of fundamental importance. Generally, 
chitosans having lower molecular weights and lower 
degrees of deacetylation exhibit greater solubility and faster 
degradation than their high-molecular-weight counterparts 
(Zhang and Neau 2001, 2002; Köping-Höggård et al 2004; 
Mao et al 2004; Ren et al 2005).
Positively charged chitosan will bind to cell membranes 
and is reported to decrease the trans-epithelial electrical 
resistance (TEER) of cell monolayers as well as to increase 
paracellular permeability (Artursson et al 1994; Dodane et al 
1999). Chitosan solutions have been shown to increase trans- 
and para-cellular permeability in a reversible, dose-dependent 
manner that also depends on the molecular weight and degree 
of deacetylation of the chitosan (Schipper et al 1996). The 
mechanism of action, which appears to be mediated by the 
positive charges on the chitosan, includes interactions with 
the tight junction proteins occludin and ZO-1, redistribution 
of F-actin, and slight destabilization of the plasma membrane 
(Dodane et al 1999; Fang et al 2001; Thanou, Verhoef, 
Junginger, 2001). Thus, the ability of chitosan to enhance 
permeation is influenced by the pH of the environment. As 
mentioned above, trimethyl chitosan derivatives are soluble at 
higher pH than unmodified chitosan. For example, a trimethyl 
derivative with 61.2% quaternization was able to decrease 
TEER of Caco-2 cells and increase mannitol permeability at 
pH 7.4, unlike unmodified chitosan hydrochloride or 12.3% 
quaternized trimethyl chitosan (Kotzé et al 1999).
Chitosan is also mucoadhesive (Deacon et al 2000). 
Mucus is a blend of molecules including salts, lysozyme, and 
mucins, which are highly hydrated glycoproteins primarily 
responsible for the viscoelastic properties of mucus. Sialic 
acid residues on mucin have a pKa of 2.6, making them 
negatively charged at physiological pH (Deacon et al 2000; 
Wang et al 2000). Therefore, the presence of mucus affects 
free drug permeability as well as the uptake of particulates 
by forming both a physical barrier to diffusion as well as by 
interacting electrostatically with cationic molecules, such as 
chitosan. Derivatives of chitosan such as trimethyl chitosan 
retain their mucoadhesive properties, albeit to a lesser extent 
than unmodified chitosan (Snyman et al 2003). In addition, 
formation of chitosan into micro- and nano-particles also 
preserves mucoadhesion (Behrens et al 2002; Kockisch et 
al 2003; Dhawan et al 2004).
Chitosan is generally considered nontoxic and bio-
degradable, with an oral LD50 in mice of over 16 g/kg 
(Hirano 1996). Antimicrobial, antifungal, and wound-healing 
properties have also been reported (Singla and Chawla 2001). 
The safety of chitosan, its ability to prolong residence time in 
the gastrointestinal tract through mucoadhesion, and its ability 
to enhance absorption by increasing cellular permeability 
have all been major factors contributing to its widespread 
evaluation as a component of oral dosage forms.
Chitosan solutions as permeation 
enhancers
The effects of chitosan solutions on intestinal cells have 
been extensively investigated (Schipper et al 1996, 1997, 
1999). Absorption enhancement was found to depend on 
both molecular weight and degree of deacetylation. Polymers 
with low molecular weight and < 65% deacetylation do not 
Figure 1
Figure 1. The mean Papp of mannitol across Caco-2 cell monolayers during 60 min
exposure to 50 µg/ml chitosan. The numbers associated with the bars in the graph show
the molecular weight of the studied chitosans in kD. The Papp of mannitol across
untreated monolayers was 2.4 ± 0.2 (×10
-7) cm/sec, and is indicated in the figure by the
horizontal line. Data are given as the mean of 3-4 experiments. Error bars represent
standard deviations. Reprinted from Pharm Res 13, Schipper NG, Varum KM, Artursson
P, Chitosans as absorption enhancers for poorly absorbable drugs 1: Influence of
molecular weight and degree of acetylation on drug transport across human intestinal
epithelial cells (Caco-2). 1686-1692, Copyright (1996), with kind permission of Springer
Science and Business Media.
Figure 1  The mean Papp of mannitol across Caco-2 cell monolayers during 60 
minutes’ exposure to 50 µg/ml chitosan. The numbers associated with the bars in 
the graph show the molecular weight of the studied chitosans in kDa. The Papp of 
mannitol across untreated monolayers was 2.4 ± 0.2 (×10
–7) cm/sec, and is indicated 
in the figure by the horizontal line. Data are given as the mean of 3–4 experiments. 
error bars represent standard deviations. reprinted from Schipper NG, vårum KM, 
Artursson P. 1996. Chitosans as absorption enhancers for poorly absorbable drugs. 
1: influence of molecular weight and degree of acetylation on drug transport across 
human intestinal epithelial (Caco-2) cells. Pharm Res, 13:1686–92. Copyright © 1996, 
with permission from Springer Science and Business Media.international Journal of Nanomedicine 2006:1(2) 119
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increase transport of mannitol across Caco-2 cell layers. On 
the other hand, polymers with a high degree of deacetylation 
exhibit greater cellular toxicity. The optimal combination of 
absorption enhancement and low toxicity was observed for 
polymers having a moderate degree of deacetylation and a 
high molecular weight, particularly a chitosan of 170 kDa and 
65% deacetylation (Schipper et al 1996) (Figure 1).
Incubation of Caco-2 cells with 50 µg/mL solutions of 
chitosan having various molecular weights and degrees of 
deacetylation (31 kDa, 99% DA and 170 kDa, 65% DA) 
increased permeation of the drug atenolol across cells 
(Schipper et al 1999). The fluorescently labeled chitosan was 
observed to adhere in a layer to cell surfaces. However, the 
Caco-2 cell model does not include the mucus layer normally 
present in the gastrointestinal tract. In order to evaluate the 
behavior of chitosan in the presence of mucus, drug uptake 
was studied in the mucus-secreting goblet cell line HT29-
H. In this instance, uptake of mannitol was enhanced by 
the presence of chitosan, but this enhancement was less 
than that observed in Caco-2 cells. Furthermore, binding of 
chitosan to the cell surface was reduced. Both cell surface 
binding and drug absorption could be improved by partially 
removing this mucus layer. These in vitro results were similar 
to what the authors observed in vivo after perfusion of 
atenolol through rat ileal sections for 2 hours with or without 
250 µg/mL chitosan solutions. A modest increase in effective 
atenolol permeability was observed. However, chitosan did 
not appear to increase plasma bioavailability over this time 
frame, as drug concentrations were not significantly different 
between chitosan and control samples (Schipper et al 1999). 
In contrast, intra-duodenal instillation of buserelin to rats 
led to a significant increase in bioavailability when given 
in a 1.5% (w/v) chitosan hydrochloride solution, pH 6.7 
compared with a control buffer solution (LueBen et al 1996). 
The absolute bioavailability increased from 0.1% +/– 0.1% 
to 5.1% +/– 1.5% and peak serum buserelin increased from 
6.7 +/– 1.7 ng/mL to 364.0 +/– 140.0 ng/mL for the chitosan 
solution compared with the control.
Modifications to chitosan have also been tested in efforts 
to improve mucoadhesion and permeation enhancement. 
Addition of thiol groups increases mucoadhesion through 
formation of disulfide bonds with cysteine residues on 
mucin (Bernkop-Schnürch et al 2004) and thiolated 
polymers in combination with reduced glutathione 
(GSH) can influence permeability by interfering with the 
closing of tight junctions (Bernkop-Schnürch et al 2003). 
Chitosan has reportedly been modified with thiol groups 
to form chitosan–4-thio-butylamidine (chitosan-TBA) and 
chitosan–thioethylamidine (chitosan–TEA). Incubation 
with 0.5% thiolated chitosan + 5% GSH resulted in 
increased permeability of the marker rhodamine through 
both rat and Guinea pig intestinal segments compared 
with 0.5% unmodified chitosan (Bernkop-Schnürch et al 
2004; Kafedjiiski et al 2006). Modified trimethyl chitosan 
derivatives have also been evaluated in vivo for absorption   
enhancing properties. In rats, intra-jejunal administration 
of the peptide octreotide with 1% (w/v) N-trimethyl 
chitosan chloride, pH 7.4 resulted in 5 times greater serum 
bioavailability, while administration with 1% chitosan 
hydrochloride, pH 7.4 had no effect (Thanou et al 2000). 
Similar results were reported in pigs, in which 10 mg   
octreotide administration in 5% or 10% (w/v) N-trimethyl 
chitosan chloride, pH 7.4 increased bioavailability significantly 
more than administration in 1.5% chitosan hydrochloride, pH 
5.5 (Thanou, Verhoef, Verheijden, et al 2001).
Although chitosan is generally considered nontoxic, 
perfusion with 250 µg/mL chitosan solution caused 
morphological changes to rat small intestine microvilli, as well 
as increased secretion of mucin from goblet cells (Schipper et 
al 1999). Mucus may inhibit the effects of chitosan by acting 
as a diffusion barrier, by forming electrostatic interactions 
between positively charged chitosan and negatively charge 
mucins, and/or by degradation through exposure of chitosan 
to lysozyme contained in the mucus (Schipper et al 1999). 
However, the authors speculate that chitosan may ultimately 
deplete the mucus layer of intestinal cells through enhanced 
secretion of goblet cell mucus, thereby allowing remaining 
unbound chitosan to interact directly with cell surfaces. 
In addition, they speculate that formulation of chitosan in 
drug delivery systems may increase permeation by locally 
increasing the effective chitosan concentration (Schipper et 
al 1999). 
Chitosan nanoparticles for oral 
drug delivery 
The concept that chitosan in formulations such as 
nanoparticles may be more efficient than chitosan solution 
at enhancing protein uptake is supported by several recent 
studies (Fernandez-Urrusuno et al 1999; Pan et al 2002; 
Ma and Lim 2003; Ma et al 2005). Incubation of Caco-2 
cells with chitosan–insulin nanoparticles resulted in greater 
cell binding and uptake compared with a chitosan–insulin 
solution (Ma and Lim 2003). While most chitosan in solution 
remained extracellular, a significant amount of fluorescently 
labeled nanoparticles was localized inside the cells after 
a 2-hour incubation, principally near the apical surface. international Journal of Nanomedicine 2006:1(2) 120
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Chitosan nanoparticles could also decrease the TEER of 
the cell monolayers at both pH 5.3 and 6.1, although to a 
lesser degree than the chitosan solution. Administration of 
these chitosan–insulin nanoparticles to diabetic rats led to 
prolonged reductions in serum glucose levels (Ma et al 2005). 
Administration of 50 U insulin/kg as nanoparticles (pH 5.3) 
decreased glucose levels to about 60% of baseline, while 
administration of a chitosan–insulin solution was ineffective. 
Delivery of 100 U/kg chitosan–insulin nanoparticles (pH 
5.3) decreased glucose levels to about 50% of baseline 
starting around 12 hours after delivery and maintained this 
level until at least 24 hours (Figure 2). Delivery of 100 U/kg 
chitosan–insulin nanoparticles (pH 6.1) resulted in a faster 
onset of action (2 hours after delivery) but less of a decrease in 
glucose levels (60%–75% of baseline). Fluorescently labeled 
nanoparticles were also observed in association with rat 
intestinal epithelia and some particles had been internalized 
3 hours after delivery. 
These results confirm prior reports on the effectiveness 
of chitosan–insulin nanoparticles (Fernandez-Urrusuno 
et al 1999; Pan et al 2002). Oral administration of insulin 
to diabetic rats in the form of chitosan nanoparticles 
approximately 300 nm in size and positively charged led to 
reduced plasma glucose levels 10 hours after delivery (Pan 
et al 2002). At a dose of 14 U insulin/kg, rats exhibited a 
greater drop in glucose than was achieved using a control 
insulin–chitosan solution. An even greater decrease in 
glucose levels was observed by increasing the nanoparticle 
dose to 21 U insulin/kg. The authors theorize that chitosan 
nanoparticles may protect insulin from gastrointestinal 
degradation and may enhance uptake through mucoadhesion 
and/or permeation enhancement.
Similarly, Fernandez-Urrusuno et al (1999) reported 
the formation of 300–400-nm positively charged insulin–
chitosan nanoparticles formed using ionic gelation of 
chitosan hydrochloride with pentasodium tripolyphosphate. 
Mucosal (intranasal) administration of the insulin-chitosan 
nanoparticles to rabbits caused a 40% drop in blood glucose 
level. This drop was significantly greater than was observed 
following intranasal administration of an insulin–chitosan 
solution, despite using a greater dose of chitosan in the solu-
tion than in the nanoparticles (0.43 mg/kg vs 0.16 mg/kg).
In addition to hydrophilic drugs, lipophilic drugs such 
as cyclosporine A have also been efficiently encapsulated 
in chitosan nanoparticles (El-Shabouri 2002). Oral 
administration to dogs of cyclosporine A encapsulated in 
chitosan hydrochloride nanoparticles (~150 nm, + 30 mV) 
led to peak cyclosporine A plasma levels of 2.8 µg/mL 
at 3 hours, falling off to less than 1.0 µg/mL at 24 hours. 
Chitosan nanoparticle delivery led to 73% greater relative 
bioavailability of drug compared with the commercial 
microemulsion Neoral
, while delivery of similarly sized 
cationic nanoparticles formed with gelatin-A led to 18% 
greater bioavailability. However, delivery of smaller 
negatively charged sodium glycocholate nanoparticles led 
to decreased bioavailability, indicating the cationic nature 
of the particles may be important for efficacy.
Coating lipid nanoparticle formulations with a chitosan 
layer can also confer beneficial effects. Intra-gastric delivery 
of chitosan-coated lipid nanoparticles containing calcitonin 
to rats led to a 27% drop in serum calcium level that was 
maintained for 24 hours (Prego et al 2005). This drop in 
calcium was significantly greater than that achieved by 
delivery of calcitonin solution or by delivery of calcitonin 
in the un-coated lipid nanoemulsion. Recently, Takeuchi 
et al (2005) compared the properties of chitosan-coated 
multi-lamellar liposomes (CS-Lip, ~4–4.6 µm) with chitosan-
coated, submicron-sized liposomes (ssCS-Lip, ~300–400 nm) 
after intra-gastric delivery to rats. They reported improved 
mucoadhesion and gastrointestinal retention of the smaller 
particles. In addition, confocal microscopy revealed that the 
submicron-sized particles were able to penetrate the mucus 
layer of enterocytes, unlike the multi-lamellar liposomes. 
Figure 2
Figure 2. Serum glucose levels of streptozotocin-induced diabetic rats (mean ± S.D.,
n=8) after the oral administration of (a) F5.3np at insulin doses of 50 U/kg (∆) and 100
U/kg (s); (b) insulin solution at 50 U/kg (q) and 100 U/kg (n); (c) F5.3np after cross-
flow filtration, whose insulin dose was 100 U/kg before cross-flow (×). Reprinted from
Int J Pharm, 293, Ma Z, Lim TM, Lim L-Y, Pharmacological activity of peroral
chitosan-insulin nanoparticles in diabetic rats, 271-280, Copyright (2005), with kind
permission from Elsevier.
Figure 2  Serum glucose levels of streptozotocin-induced diabetic rats 
(mean ± SD, n = 8) after the oral administration of F5.3np at insulin doses of 
50 U/kg (∆) and 100 U/kg (s); insulin solution at 50 U/kg (q) and 100 U/kg (n); 
F5.3np after cross-flow filtration, whose insulin dose was 100 U/kg before cross-
flow (×). reprinted from Ma Z, Lim TM, Lim L-Y. 2005. Pharmacological activity 
of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm, 293:271–80. 
Copyright © 2005, with permission from elsevier.international Journal of Nanomedicine 2006:1(2) 121
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Administration of calcitonin (500 IU/rat) in the form of 
chitosan-coated ss-Lip resulted in a significantly greater drop 
in blood calcium levels than was achieved with CS-Lip or 
control calcitonin solution and lasted up to 120 hours.
The ability of chitosan to chelate metal ions has also 
been exploited to inhibit metallo-proteinase enzymes in 
the lumen and brush border. Unfortunately, LueBen et al 
(1997) reported that, despite binding metal cations, chitosan 
alone was not sufficient to inhibit enzymes such as trypsin 
and carboxypeptidase B. This led to the development of 
modified chitosans with greater metal complexing abilities. 
Chitosan–EDTA conjugates displayed increased binding 
of divalent cations and inhibition of aminopeptidase N and 
carboxypeptidase A (zinc-dependent proteases). However, 
despite binding calcium, these conjugates were not effective 
against calcium-dependent serine proteases including trypsin, 
chymotrypsin, and elastase (Bernkop-Schnürch and Krajicek 
1998). 
Competitive enzyme inhibitors such as antipain or 
chymostatin can also be covalently attached to chitosan 
through the amine groups, while still allowing chitosan to 
retain some mucoadhesive properties (Bernkop-Schnürch and 
Scerbe-Saiko 1998). The use of enzyme inhibitors conjugated 
directly to the chitosan may improve drug bioavailability by 
localizing the inhibitory effect to the site of drug uptake, as 
well as reducing toxicity from administration of the inhibitor. 
A substantial amount of insulin (40%–60%) remained 
undegraded 4.5 hours after incubation in artificial intestinal 
fluid when it was encapsulated in a chitosan–EDTA matrix 
in which 10% of the chitosan–EDTA was substituted with a 
conjugate containing a Bowman-Birk enzyme inhibitor. In 
contrast, 90% insulin was degraded from the chitosan–EDTA 
matrix without the additional inhibitor (Bernkop-Schnürch 
2000). The use of such chitosan–inhibitor conjugates may 
represent a valuable approach to improve protection from 
drug degradation and achieve more effective oral drug 
delivery.
Chitosan nanoparticles for oral 
gene delivery
Increasingly, nucleic acids are being applied as drugs, both for 
vaccination and therapeutic gene expression. Chitosan–DNA 
nanoparticles may be readily formed by coacervation between 
the positively charged amine groups on the chitosan and 
negatively charged phosphate groups on the DNA (Leong 
et al 1998; Mao et al 2001). Mao et al (2001) explored 
the conditions under which chitosan–DNA nanoparticles 
formed and found that discrete particles formed at chitosan 
concentrations of 50–400 µg/mL and DNA concentrations 
of 40–80 µg/mL, where buffer solutions were at pH 5.5 and 
temperature was 55
oC. Sodium sulfate (25 mM) was added as 
a desolvating agent to enhance the phase separation (Figure 
3). Particle formation was dependent on the N/P ratio (amine 
groups on chitosan/phosphate groups on DNA) and N/P ratios 
of 3–8 yielded 150–250-nm particles with surface charges 
of approximately + 15 mV . 
The effect of chitosan molecular weight and charge 
ratio on particle formation was tested by depolymerizing 
102 kDa, 89.4% deacetylated chitosan into smaller oligomers 
(MacLaughlin et al 1998). At a +/– charge ratio of 6:1, 
complex size decreased from approximately 500 nm for a 
540 kDa, 82.3% deacetylated chitosan to a plateau of around 
100 nm for the depolymerized chitosans of 32, 24, and 7 kDa. 
Incubation of the complexes with saline and 10% serum 
resulted in dissociation of the particles formed at all charge 
ratios with 7 kDa chitosan. On the other hand, only high-
molecular-weight complexes (540 and 102 kDa chitosans) 
formed at low charge ratios (0.5:1 and 1:1) dissociated, 
while 2:1 complexes remained stable and 6:1 complexes 
aggregated. At a +/– ratio of 2:1, optimal transfection of Cos-
1 cells was achieved in the absence of serum with 102 kDa 
chitosan particles, and in the presence of 10% serum by 
540 kDa chitosan particles. However, the levels achieved 
Figure 3
Figure 3. Ternary phase diagram of complex coacervation between pRE-luciferase
plasmid and chitosan at 55∞ C in 50 mM Na2SO4. Sodium sulfate solution was regarded
as one component, since the concentration change in the experiment range was minimal.
The region to the right of line ABC depicts the conditions under which phase separation
occurred. The concentration ranges in the small grid area yielded distinct particles as
observed under a phase contrast microscope. Reprinted from J Control Release, 70, Mao
H-Q, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW,
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection
efficiency, 399-421, Copyright (2001), with kind permission from Elsevier.
Figure 3  Ternary phase diagram of complex coacervation between pre-luciferase 
plasmid and chitosan at 55°C in 50 mM Na2SO4. Sodium sulfate solution was 
regarded as one component, since the concentration change in the experiment 
range was minimal. The region to the right of line ABC depicts the conditions 
under which phase separation occurred. The concentration ranges in the small 
grid area yielded distinct particles as observed under a phase contrast microscope. 
reprinted from Mao H-Q, roy K, Troung-Le vL, et al. 2001. Chitosan-DNA 
nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. 
J Control Release, 70:399–421. Copyright © 2001, with permission from elsevier.international Journal of Nanomedicine 2006:1(2) 122
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were still over 200 times lower than were achieved with 
Lipofectamine. The addition of an endosomolytic peptide 
increased expression by only a limited extent (about 4 
times). However, delivery of the chitosan–endosomolytic 
nanoparticles by direct instillation into the intestinal lumen 
of rabbits yielded greater chloramphenicol acetyl transferase 
(CAT) expression than administration of either a lipid-DNA 
formulation or naked plasmid DNA.
The effect of degree of deacetylation of chitosan on 
nanoparticle formation has also been investigated (Kiang, 
Bright, et al 2004). For chitosans of the same molecular 
weight (390 kDa), decreasing the degree of polymer 
deacetylation required increasing the amount of chitosan in 
order to achieve complete DNA complexation. While 90% 
deacetylated chitosan could fully complex DNA at a +/– ratio 
of 3.3:1, the required +/– ratio increased to 9:1 for chitosan 
with a 62% degree of deacetylation. In addition, decreasing 
the degree of deacetylation of the polymer produced 
nanoparticles that were less stable in the presence of serum 
proteins, resulting in lower levels of in vitro transfection. On 
the other hand, gene expression after intramuscular injection 
in mice was enhanced for the less stable 62% deacetylated 
nanoparticles compared with 70% and 90% deacetylated 
chitosan particles. 
Complexation of DNA with low-molecular-weight, 
highly deacetylated chitosan (5 kDa, 99% DA) has also been 
reported (Liu et al 2005). The results of circular dichroism 
suggested that chitosan binds to the minor groove of DNA, 
although DNA retains its native B conformation. As expected, 
DNA binding was enhanced at acidic pH owing to protonation 
of chitosan amines and was substantially reduced at pH 12. 
A dependence of complex formation on N/P ratio was also 
observed. At pH 5.4, a chitosan:DNA charge ratio of 1:4 
produced only aggregates and free DNA. At a ratio of 2:1 both 
spherical and irregularly shaped complexes were observed, 
while an increase in charge ratio to 8:1 produced compact 
spherical particles of less than 100 nm. 
The reactive amine groups on chitosan can serve as 
functional groups for the attachment of a variety of potential 
targeting ligands. The transferrin receptor is responsible 
for iron uptake and is present on many mammalian cells. 
However, attachment of transferrin to chitosan nanoparticles 
increased transfection efficiency only modestly (Mao et al 
2001). Luciferase levels for the modified nanoparticles were 
only 2–3 times the levels of unmodified particles in HEK293 
cells and less than 50% higher in HeLa cells. On the other 
hand, attachment of the knob domain of the adenovirus 
capsid fiber protein produced levels about 6–7 times greater 
than unmodified particles in HEK293 cells and 130 times 
greater in HeLa cells (Mao et al 2001). Incubation with free 
knob reduced transfection to basal levels, indicating that the 
uptake was most likely via receptor-mediated endocytosis. 
However, these levels were still below those achieved with 
Lipofectamine. 
While transferrin or knob conjugations have the potential 
to increase uptake in a variety of tissues, galactose conjugation 
has been proposed as a means to increase specific hepatocyte 
targeting via the asialoglycoprotein receptor (Gao et al 2003; 
Kim et al 2004). Conjugation of lactobionic acid to low-
molecular-weight chitosan (~21 kDa) produced galactosylated 
chitosan able to complex DNA into nanoparticles (Gao et al 
2003). These particles had a mean size of approximately 
350 nm while particles from unmodified low-molecular-
weight chitosan were around 220 nm. Transfection of 
galactosylated chitosan nanoparticles into the liver cell lines 
HepG2, L-02, and SMMC-7721 modestly improved levels 
of β-galactosidase expression compared with unmodified 
chitosan nanoparticles. Transfection of HeLa cells lacking the 
asialoglycoprotein receptor was very low for both modified 
and unmodified chitosan nanoparticles. Increasing the degree 
of galactosylation from 0% to 8.3% resulted in about 6 times 
greater transfection in HepG2 cells, but not in HeLa cells, 
suggesting that the galactosylated particles were internalized 
via receptor mediated endocytosis.
Lactobionic acid was also conjugated to a low-
molecular-weight, water-soluble chitosan (Kim et al 2004). 
Nanoparticles formed at an N/P ratio of 10 had a size of 
approximately 100 nm and a charge of + 6 mV, indicating 
suitability for uptake through fenestrated liver endothelium. 
Transfection levels were low, however, and were carried 
out in the presence of calcium, which has been shown to 
enhance in vitro transfection. Similar to the results reported 
by Gao et al (2003), luciferase expression was the same 
for both galactosylated and nongalactosylated chitosan 
nanoparticles in HeLa cells but was substantially enhanced 
in HepG2 cells. In addition, transfection was inhibited by 
the presence of free galactose, indicating the uptake was 
likely through the asialoglycoprotein receptor. Transfection 
of the galactosylated chitosan nanoparticles could be further 
enhanced by addition of polyethylenimine (PEI), which 
may act to disrupt endosomes through pH buffering (Kim 
et al 2005). Addition of PEI to both galactosylated and 
nongalactosylated chitosan resulted in nanoparticles with 
increased zeta potentials and improved transfection in both 
HeLa and HepG2 cells. In HepG2 cells luciferase levels were 
greater for galactosylated chitosan with 1 or 2 µg added PEI international Journal of Nanomedicine 2006:1(2) 123
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than for unmodified chitosan, while addition of 5 µg of PEI 
produced similar levels of transfection for both chitosan 
formulations. Transfection levels for both chitosans were 
also similar in HeLa cells, which lack the asialoglycoprotein 
receptor. The results suggest that uptake occurred through 
the asialoglycoprotein receptor at lower PEI levels but was 
receptor-independent with higher PEI coating. Interestingly, 
toxicity of the galactosylated chitosan PEI nanoparticles was 
less than that of plain PEI nanoparticles, while transfection 
levels were similar or greater, indicating that such synergistic 
formulations may be able to take advantage of the desirable 
properties of several polymers.
Potential endosomolytic agents other than PEI have also 
been tested in combination with chitosan. Co-encapsulation 
of chloroquine into chitosan–DNA nanoparticles resulted in 
the transfection of 3 times more HEK293 cells than control 
nanoparticles, although fluorescence intensity was 10–20 
times lower than cells transfected with Lipofectamine (Mao 
et al 2001). Similarly, there was no significant difference in 
Luciferase expression between HEK293 cells transfected 
with chitosan nanoparticles with or without chloroquine, 
indicating only a modest effect. The pH-sensitive polymer 
poly(propyl acrylic acid) (PPAA), which can disrupt 
membranes at acidic pH (Cheung et al 2001), has also been 
combined with chitosan to form DNA nanoparticles that 
exhibited enhanced transfection in both HEK293 cells and 
HeLa cells (Kiang, Bright, et al 2004). Chitosan, DNA, and 
PPAA were co-localized at 24 hours, while at later time 
points DNA and PPAA appeared diffuse in the cell and did 
not co-localize with lysosomes, indicating escape from the 
endosomal–lysosomal pathway.
These in vitro studies with reporter genes showed that 
chitosan could be readily formulated into DNA nanoparticles 
able to transfect some cell lines better than others. The size 
and stability of the particles could be influenced by the 
molecular weight of the chitosan, the degree of deacetylation, 
and the charge ratio at which the particles were formed. 
Further modifications to the nanoparticles through ligand 
conjugation or the addition of endosome-disrupting molecules 
may further overcome some of the transport barriers to cell 
transfection and improve expression levels, although results 
so far have been modest. However, these studies established 
the basis for using such chitosan particles to deliver genes in 
vivo both as vaccines and in disease treatment.
Delivery of chitosan–DNA vaccines
One area of oral DNA delivery that has received considerable 
attention is DNA vaccination. Protein-based subunit vaccines 
primarily activate humoral immune responses that lead to the 
production of circulating antibodies against the delivered 
antigen. However, transfection with antigen-encoding DNA 
can generate both antibody-based and cell-mediated immune 
responses (Leitner et al 2000). In addition, unmethylated 
bacterial CpG motifs in the plasmid DNA act as adjuvants 
to stimulate the immune response (Krieg 2001). Oral vaccine 
delivery may be particularly desirable not only for patient 
preference, but also for the ability to generate immune 
responses at mucosal surfaces, where many pathogens 
normally invade (Clark et al 2001). 
Orally administered particulate vaccines are generally 
thought to be internalized by antigen-sampling membranous 
(M) cells in intestinal Peyer’s patches. These M cells have 
a thinner glycocalyx and less organized microvilli than 
enterocytes and are known to internalize and transcytose 
particles to underlying lymphocytes and antigen-presenting 
cells (Neutra et al 1987; Jepson et al 1996; Clark et al 
2001). Particles up to 10 µm in diameter can be internalized 
into Peyer’s patches and particles less than 5 µm can be 
transported to draining lymph nodes and the spleen (Eldridge 
et al 1990). 
Oral administration to mice of chitosan–DNA nano-
particles containing the gene for the dominant peanut 
allergen Arah2 resulted in the production of secretory IgA 
and serum IgG2a, as well as a reduced increase in IgE (Roy 
et al 1999). This immune response was not observed for mice 
given naked plasmid DNA. Delivery of the chitosan-DNA 
nanoparticles also mitigated the anaphylactic response to 
peanut challenge, possibly through redirection of the immune 
response away from an allergic, IgE-based response to a more 
TH1-dominated response (Figure 4). 
However, in contrast to the assumption that M cells are 
the primary absorptive cells for particulates, delivery of 
LacZ-containing chitosan nanoparticles revealed staining 
in intestinal enterocytes (Roy et al 1999). The ability of 
nanoparticles to be internalized by non-Peyer’s patch 
intestinal tissue has been previously reported (Desai et al 
1996; Desai et al 1997). PLGA particles up to 10 µm could 
be internalized by Caco-2 cells, considered a model for 
intestinal epithelium (Desai et al 1997). PLGA particles 
(100 nm–10 µm) could also be internalized by both rat Peyer’s 
patch and nonPeyer’s patch intestinal tissues, although uptake 
decreased substantially with increasing size (Desai et al 
1996). Uptake is likely to depend not only on size, but also 
on polymer composition. More hydrophobic polystyrene and 
poly(methyl methacrylate) microparticles were absorbed to 
a greater extent than PLGA particles, while cellulose-based international Journal of Nanomedicine 2006:1(2) 124
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materials showed poor absorption (Eldridge et al 1990). In 
the study by Eldridge et al (1990), uptake by Peyer’s patches 
did appear to predominate, as microparticles were reportedly 
not observed in other tissues. However, it may be that the size 
of the chitosan nanoparticles (~100–200 nm) (Roy et al 1999) 
coupled with their hydrophobicity and the mucoadhesive 
properties of chitosan led to increased uptake by the far more 
abundant enterocytes. 
Chitosan–DNA nanoparticles have also been successfully 
used to generate an immune response to the dust mite allergen 
Der p 1 (Chew et al 2003). Oral delivery of two feedings of 
chitosan nanoparticles containing 50 µg Der p 1 (114–222) 
DNA was followed 13 weeks later by an intramuscular 
boost with 50 µg Der p 1 (1–222) DNA in saline and 
electroporation. While intramuscular injection alone was 
unable to generate immune responses to the right domain of 
the Der p 1 antigen (114–222), oral priming led to detectable 
levels of IgG2a and low levels of IgA against this domain. 
IgG1 was not detected, suggesting a shift to a TH1-dominated 
immune response, similar to what was observed by Roy et al 
(1999). Oral delivery of naked Der p1 DNA or empty vector 
DNA in chitosan nanoparticles did not lead to anti-Der p 1 
antibody responses.
Interestingly, while Roy et al (1999) reported increased 
antibody levels by 3–4 weeks, the chitosan-Der p 1 
formulation did not result in antibody detection until 8 
weeks after delivery. The authors speculate that the delayed 
appearance of the antibodies may be due to the 10-fold higher 
concentration of chitosan used (0.2%), which may have 
retarded DNA release from the particles and delayed the onset 
of action, highlighting the effect formulation conditions can 
have on the kinetics of transgene expression.
Oral delivery of chitosan DNA nanoparticles was also 
tested as a vaccine strategy against the intracellular parasite 
Toxoplasma gondii (Bivas-Benita et al 2003). In this study, 
both chitosan microparticles loaded with the parasite protein 
GRA1 and chitosan nanoparticles formed with GRA1 DNA 
were compared for their ability to generate anti-GRA1 
antibodies. Low levels of anti-GRA1 were detected in 
sera 1 month after intragastric delivery of 3 x 50 µg protein 
microparticles, although no response was detected for mice 
given 3 x 50 µg DNA nanoparticles. Boosting with a second 
round of intragastric micro- or nano-particles increased 
the antibody response somewhat, although not as well as 
boosting by intramuscular injection of DNA. In contrast to 
the studies above, which reported the generation of TH1-type 
immune responses following oral delivery of chitosan–DNA 
nanoparticles, the authors reported the IgG2a/IgG1 ratio after 
oral priming with chitosan-DNA nanoparticles and boosting 
by intramuscular injection was 0.1, indicating a shift towards 
a TH2 driven response that would not be protective against   
T. gondii. In this study, the authors formed the chitosan DNA 
nanoparticles with an N/P ratio of 6:1 and examined antibody 
responses at 4 weeks. This ratio is higher than that used by 
Roy et al (1999). Similar to the finding of Chew et al (2003), 
who did not report antibody generation until 8 weeks, it may 
be that the GRA1 nanoparticles were too stable to release 
DNA sufficiently over the time course examined. The GRA1 
nanoparticles reportedly did not release any DNA after 8 days 
incubation in PBS pH 7.2, 25
oC, suggesting the particles 
were fairly stable and likely to release DNA only slowly by 
enzymatic chitosan degradation (Bivas-Benita et al 2003). 
Chitosan itself may also have properties that affect 
immune responses, influencing its use in vaccine systems. 
Induction of varying levels of TNF-alpha from monocytes 
was reported for chitosans of 40%–80% deacetylation and 
3.5–50 kDa and depended on molecular weight, degree of 
deacetylation, and neutral solubility (Otterlei et al 1994). 
In addition, purified influenza surface antigens given intra-
nasally to mice with 1% (w/v) chitosan glutamate solution 
resulted in increased levels of IgG, IgA, and antibody-
secreting lymphocytes compared with intra-nasal delivery 
of the surface antigens alone (Bacon et al 2000). Intravenous 
injection of phagocytosable (1–10 µm) chitosan particles 
Figure 4
Figure 4. Anaphylactic response of mice after Arah2 challenge. Mice (n=6) were
immunized with a single dose of chitosan-pArah2 nanoparticles (single dose, G1; ♦);
with two doses (one week apart) of chitosan-pArah2 nanoparticles (G2; <); with ‘naked’
pArah2 (G3; =); or were not immunized (G4; no symbol). Mice were then sensitized
with oral and intraperitoneal doses of crude peanut extract, challenged intraperitoneally
with recombinant Arah2 protein, and anaphylaxis was then scored on a scale of 0 to 5.
Results represent average anaphylactic response from two separate experiments.
Reprinted from Nat Med, 5, Roy K, Mao H-Q, Huang SK, Leong KW, Oral gene delivery
with chitosan-DNA nanoparticles generates immunologic protection in a murine model of
peanut allergy, 387-391, Copyright (1999), with kind permission from Nature Publishing
Group.
Figure 4  Anaphylactic response of mice after Arah2 challenge. Mice (n = 6) were 
immunized with a single dose of chitosan-pArah2 nanoparticles (single dose, G1; 
♦); with 2 doses (1 week apart) of chitosan-pArah2 nanoparticles (G2; <); with 
“naked” pArah2 (G3; =); or were not immunized (G4; no symbol). Mice were 
then sensitized with oral and intraperitoneal doses of crude peanut extract, 
challenged intraperitoneally with recombinant Arah2 protein, and anaphylaxis 
was then scored on a scale of 0–5. results represent average anaphylactic 
response from 2 separate experiments. reprinted from roy K, Mao HQ, Huang 
SK, et al. 1999. Oral gene delivery with chitosan–DNA nanoparticles generates 
immunologic protection in a murine model of peanut allergy. Nat Med, 5:387–91. 
Copyright © 1999, with permission from Nature Publishing Group.international Journal of Nanomedicine 2006:1(2) 125
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primed alveolar macrophages to release a burst of superoxide 
anion, although to a lower extent than injection of chitin 
particles (Shibata et al 1997). However, soluble chitosan 
and chitin oligosaccharides did not have this effect and 
culturing mouse spleen cells with either chitosan particles or 
soluble chitosan oligosaccharides did not lead to detectable 
levels of the macrophage-activating cytokine IFN-gamma. 
Furthermore, chitosan–DNA nanoparticles formed using the 
method of Mao et al (2001) did not result in the secretion 
of cytokines TNF-alpha, IL-1 beta, IL-6, or IL-10 after 
incubation in a macrophage cell line (Chellat et al 2005). 
However, oral feeding of 1–3 mg chitosan solution (80 kDa, 
85% deacetylation) to rats resulted in chitosan uptake by 
macrophages and dendritic cells and increased levels of IL-4 
and TGF-beta mRNA in Peyer’s patch cells. Feeding 3 mg 
(but not 1 mg), harvesting the cells, and restimulating them 
with 10 µg/mL chitosan also resulted in increased IL-10 
secretion by Peyer’s patch, mesenteric lymphocyte, and spleen 
cells. Therefore it seems that chitosan may have application 
as a vaccine adjuvant, but that these properties are likely 
to depend on the type and dose of chitosan used, as well as 
the delivery method. A fuller understanding of the nature 
of chitosan-mediated immune modulation, particularly in 
the context of nanoparticle delivery, will require additional 
investigation.
Use of chitosan–DNA nanoparticles to 
deliver therapeutic genes
In addition to oral vaccination, another attractive application 
is the oral delivery of DNA for therapeutic gene expression 
as a so-called “gene pill”. The benefits of such a delivery 
system have been delineated by Sheu et al (2003) and include 
safety, patient compliance, and dose regulation. It is worth 
noting, however, that one of the arguments proposed for 
increased safety from an oral nonviral DNA pill is targeting 
to short-lived gut epithelial cells and lack of systemic cell 
transfection. However, plasmid DNA can be detected in 
systemic tissues after oral delivery, albeit at very low copy 
numbers (Bowman et al 2005) and oral delivery of DNA 
vaccines can produce detectable systemic immune responses, 
indicating that the effects of an orally delivered formulation 
may not be locally confined.
We have also explored this oral gene delivery system 
for gene therapy of hemophilia, by delivering the Factor IX 
gene to mice through feeding. The DNA nanoparticles were 
synthesized by complexing chitosan with human factor IX 
DNA that was driven by a β-actin promoter. The initial dose 
of 25 µg DNA led to a decline of the hFIX level in plasma of 
C57bl/6J mice from 37 ng/mL on day 7 to 21 ng/mL on day 
28, even with a repeat feeding at day 14 (Okoli et al 2000). 
The decline appeared to coincide with the rise in anti-hFIX 
antibody level. At all time points, hFIX levels in control 
mice, which were fed the same dose of naked DNA, were not 
significantly different from those of naïve mice. 
A therapeutic effect following oral administration was 
also demonstrated for delivery of chitosan nanoparticles 
containing the gene for murine erythropoietin (mEPO) 
(Chen et al 2004). Using chitosan with a molecular weight of 
300 kDa and the method of particle formulation reported by 
Mao et al (2001), the authors formed DNA nanoparticles of 
approximately 100 nm in diameter with a charge of + 10 mV 
at pH 5.7. Oral delivery of the chitosan–mEPO nanoparticles 
at a dose of 50 µg DNA led to increased hematocrit. This rise 
in hematocrit was not detected in naive mice or in mice given 
naked mEPO plasmid DNA (Figure 5).
The gene for human coagulation factor VIII (FVIII) has 
also been successfully administered to mice in the form of 
chitosan-DNA nanoparticles. Our research has focused on 
using chitosan with a molecular weight of 390 kDa and both 
70% and 84% deacetylation. While we have also employed 
the method of Mao et al (2001), in our hands, nanoparticles 
formed with chitosan and the approximately 10 kb factor VIII 
plasmid DNA were around 250–300 nm in size, with a zeta 
potential of + 10 mV at pH 5.7. Delivery of 600 µg FVIII DNA 
in the form of chitosan nanoparticles led to plasma factor VIII 
levels equivalent to 0.02–0.04 IU/mL (2%–4% activity) in 
hemophilia A mice. In addition, delivery of chitosan–FVIII 
Figure 5.
Figure 5. mEpo expression and its physiological effect test. Hematocrit was measured
every two days in mice fed with (=) chitosan-mEPO and doxycycline (200 µg/mL), n=9;
chitosan-mEpo alone, n=3; (♦) doxycycline (200 µg/mL) alone, n=4; (<) naked mEpo
and doxycycline (200 µg/mL), n=5. ↓ indicating the mice fed with ‘naked mEpo DNA or
chitosan-Epo. Reprinted from World J Gastroenterol, 10, Chen J, Yang W-L, Li G, Qian
J, Xue J-L, Fu S-K, Lu D-R, Transfection of mEPO gene to intestinal epithelium in vivo
mediated by oral delivery of chitosan-DNA nanoparticles, 112-116, Copyright (2004),
with kind permission.
Figure 5  mepo expression and its physiological effect test. Hematocrit was 
measured every 2 days in mice fed with (=) chitosan-mePO and doxycycline 
(200 µg/mL), n = 9; chitosan-mepo alone, n = 3; (♦) doxycycline (200 µg/mL) alone, 
n = 4; (<) naked mepo and doxycycline (200 µg/mL), n = 5. ↓ indicates the mice fed 
with “naked” mepo DNA or chitosan-epo. reprinted from Chen J, Yang wL, Li G, et 
al. 2004. Transfection of mepo gene to intestinal epithelium in vivo mediated by oral 
delivery of chitosan-DNA nanoparticles. World J Gastroenterol, 10:112–16. Copyright 
© 2004, with permission from elsevier.international Journal of Nanomedicine 2006:1(2) 126
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DNA nanoparticles led to significantly greater levels of 
phenotypic bleeding correction than delivery of naked 
plasmid DNA, with 13/20 mice fed with high (600 µg) or 
medium (250 µg) DNA doses exhibiting bleeding correction 
1 month after nanoparticle administration. On the other hand, 
delivery of 50 µg of chitosan–FVIII DNA nanoparticles led 
to detection of FVIII plasmid DNA in multiple tissues, but 
did not appear to lead to significant levels of plasma FVIII 
protein (Bowman et al 2005). These are substantially larger 
DNA doses than those employed by Okoli et al (2000) (25 µg 
DNA) and Chen et al (2004) (50 µg DNA). However, factor 
VIII is a large protein that undergoes multiple processing 
and glycosylation events. It also must associate with the 
carrier protein von Willebrand factor to prolong its plasma 
half-life. Therefore, it may have greater barriers to functional 
gene expression than smaller proteins such as erythropoietin 
or factor IX. 
Conclusion
Many of the issues facing effective oral protein and gene 
delivery are similar. As discussed above, these include 
the need to protect the protein or gene from the damaging 
environment of the gastrointestinal tract and to facilitate 
uptake into cells. In particular, the presence of mucus in the 
GI tract may be a complicating factor for effective particle 
delivery. Chitosan mucoadhesion can locally increase the 
concentration of a drug and thus increase the driving force for 
drug diffusion into cells, which may be advantageous even if 
the nanoparticles themselves remain trapped extracellularly 
in mucus. However, it seems likely that gene expression from 
chitosan–DNA nanoparticles is mediated by cellular uptake 
of intact particles followed by intracellular DNA release. 
In this situation, mucoadhesion may be a double-edged 
sword, prolonging residence time, but possibly entrapping 
particles, preventing them from reaching cell surfaces, and 
causing them to be swept from the intestine. The adsorption 
of gastrointestinal mucins onto the surfaces of orally 
administered chitosan nanoparticles may also affect surface 
charges and interfere with cell binding and internalization, 
particularly at lower pH where the particles are cationic. 
The interaction with and diffusion through mucus of many 
chitosan systems have not been reported. More research needs 
to be conducted on these topics for the rational design of 
the next generation of oral chitosan drug and gene delivery 
systems. 
However, the studies above indicate the feasibility of 
using chitosan nanoparticles to deliver poorly bioavailable 
drugs or to achieve in vivo gene expression. Mechanistic 
insight and information such as barriers in the macroscopic 
transport of these nanoparticles across the mucosal surface, 
nanoparticle biodistribution in different tissues, types of 
cells transfected, transgene expression kinetics, and extra- 
and intracellular release of the drug and DNA from the 
nanoparticles are needed to advance the chitosan delivery 
system. Different groups have focused on different molecular 
weight chitosans, with different degrees of deacetylation, 
producing nanoparticles of varying sizes and charge ratios. 
Some of the differences reported in the levels and time-
course of protein release or gene expression from these 
particles may be due to such formulation differences. Further 
understanding of the parameters influencing nanoparticle 
formation and uptake may allow researchers to identify the 
best combination for a particular application. While much 
work has been done in the last few years to achieve successful 
oral drug and gene delivery, the field has yet to progress 
beyond animal models and demonstrate relevant efficacy 
in humans. However, the many advantages of chitosan, 
including safety, biodegradability, ease of modification, 
ease of DNA or protein complex formation, widespread 
availability, and low cost justify the continuing development 
of this promising drug and gene delivery system. 
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